-
Mashup Score: 13
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Asian Americans, Native Hawaiian, and Other Pacific Islanders - 17 hour(s) ago
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4OCE Oncology News - 1 day(s) ago
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Project Facilitate - 3 day(s) ago
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma - PubMed - 3 day(s) ago
In February 2022, the U.S. Food and Drug Administration approved ciltacabtagene autoleucel, a chimeric antigen receptor (CAR) T cell therapy targeting the B-cell maturation antigen (BCMA), for adult patients with relapsed/refractory multiple myeloma (RRMM) after ≥4 lines of therapy including an immu …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
AbstractBackground. The impact of ongoing efforts to decrease opioid use on patients with cancer remains undefined. Our objective was to determine trends in new
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Conversations on Cancer - 3 day(s) ago
Conversations on Cancer
Source: www.fda.govCategories: General Medicine News, Onc News and JournalsTweet
FDA has granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy. https://t.co/Flkox8PMyV #OCENewsBurst